Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Abstract

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More particularly, the invention relates to achieving efficacious doses of orally administered doses docetaxel whilst maintaining acceptable safety. By providing novel means and methods, combining oral docetaxel with a CYP3A inhibitor, the inventors have established improved treatments of cancer, said methods and means providing for an improved safety profile of docetaxel as compared with the standard of treatment for docetaxel, while at the same time allowing to obtain efficacious levels of docetaxel to eradicate cancer cells.

Description

[0001] The present invention relates to chemotherapy of tumors with taxanes, especially docetaxel. More particularly, it relates to orally administered doses of docetaxel that achieve effective doses while maintaining acceptable toxicity. Background technique [0002] Cancer treatment involves a wide range of treatments. Treatments include, for example, surgery, radiation therapy, chemotherapy, immunotherapy, and cell therapy. Often, cancer treatment involves a combination of different treatment modalities, which includes a combination of different therapeutic agents. Docetaxel, a taxane, is widely used in the treatment of various cancers as part of first-line chemotherapy. Docetaxel is a cytotoxic agent whose primary mode of action is understood to involve interference with microtubule assembly and disassembly, resulting in inhibition of cell mitosis. The recommended dose is administered intravenously every three weeks, where the dose range is 75-100 mg / m 2 body surface a...

AI Technical Summary

Problems solved by technology

Despite the potential to benefit patients with increased life expectancy and quality of life, the use of docetaxel is associated with significant side effects

Images